Breaking911
@Breaking911
BREAKING: Ohio Department of Health BANS hydroxychloroquine in treating COVID-19 https://breaking911.com/breaking-ohio-
3:37 PM · Jul 29, 2020
https://twitter.com/Breaking911/status/1288604700661764098?s=20
Requirements for Dispensing or Selling Chloroquine and Hydroxychloroquine in Ohio
On July 30, 2020, rule 4729:5-5-21 of the Administrative Code goes into effect. In general, the rule prohibits all terminal distributors (including prescriber clinics, non-resident pharmacies, and institutional facilities) from selling or dispensing hydroxychloroquine and chloroquine for the treatment or prevention of COVID-19 [see paragraph (B) below]. Please be advised that this rule replaces emergency rule 4729-5-30.2 and that all approvals for the use of these medications made under that rule are no longer applicable.
4729:5-5-21 Prescription requirements for chloroquine and hydroxychloroquine.
(A) No prescription for chloroquine or hydroxychloroquine may be dispensed by a pharmacist or sold at retail by a licensed terminal distributor of dangerous drugs, including prescriptions for patients residing in Ohio dispensed or sold at retail by nonresident terminal distributors of dangerous drugs as defined in rule 4729:5-8-01 of the Administrative Code, unless the prescription bears a written diagnosis code from the prescriber or a statement indicating its veterinary medical purpose.
(B) Except as provided in paragraph (C) of this rule, prescriptions issued for chloroquine or hydroxychloroquine for prophylactic use related to COVID-19 or for the treatment of COVID-19 are strictly prohibited unless otherwise approved by the board’s executive director in consultation with the board president, at which time a resolution shall issue. Upon the effective date of this rule, all previous approvals for the use of chloroquine or hydroxychloroquine shall be deemed void and must be approved using the process outlined in this paragraph.
(C) The prohibition in paragraph (B) of this rule does not apply to prescriptions issued as part of a documented institutional review board-approved clinical trial to evaluate the safety and efficacy of the drugs to treat COVID-19. Prescriptions must include documentation that the patient is enrolled in a clinical trial.
(D) Paragraphs (B) and (C) of this rule shall also apply to medication orders and outpatient prescriptions dispensed by institutional pharmacies as defined in agency 4729 of the Administrative Code.
To assist licensees in complying with this new rule, the Board has developed the following frequently asked questions: www.pharmacy.ohio.gov/hydroxy
Anyone in the Dept of health there that tests positive for its use during or after infection with covid19 should get the death penalty.